Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jan;39(1):241–244. doi: 10.1128/aac.39.1.241

Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents.

T Yamamoto 1, G B Nair 1, M J Albert 1, C C Parodi 1, Y Takeda 1
PMCID: PMC162516  PMID: 7695314

Abstract

Vibrio cholerae O139 (173 strains) and O1 (221 strains) were tested for their in vitro susceptibilities to 39 antimicrobial agents. Both O139 and O1 strains were highly susceptible to azithromycin, cephems, minocycline, penems, and newer fluoroquinolones. O139 strains (94.8%), O1 Indian El Tor strains (97%), and Bangladeshi El Tor strains (50%) were highly resistant to streptomycin, sulfamethoxazole, and trimethoprim and moderately resistant to chloramphenicol and furazolidone, in sharp contrast to O1 Peruvian El Tor and O1 classical strains. Some Bangladeshi El Tor strains (43.3%) showed tetracycline resistance as well.

Full Text

The Full Text of this article is available as a PDF (170.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert M. J., Siddique A. K., Islam M. S., Faruque A. S., Ansaruzzaman M., Faruque S. M., Sack R. B. Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh. Lancet. 1993 Mar 13;341(8846):704–704. doi: 10.1016/0140-6736(93)90481-u. [DOI] [PubMed] [Google Scholar]
  2. Bauernfeind A. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother. 1993 Apr;31(4):505–522. doi: 10.1093/jac/31.4.505. [DOI] [PubMed] [Google Scholar]
  3. Bergan T., da Fonseca J. Comparative antibacterial activity of the penem ALP 201. Chemotherapy. 1991;37(6):413–419. doi: 10.1159/000238888. [DOI] [PubMed] [Google Scholar]
  4. Chongsa-nguan M., Chaicumpa W., Moolasart P., Kandhasingha P., Shimada T., Kurazono H., Takeda Y. Vibrio cholerae O139 Bengal in Bangkok. Lancet. 1993 Aug 14;342(8868):430–431. doi: 10.1016/0140-6736(93)92841-g. [DOI] [PubMed] [Google Scholar]
  5. Fisher-Hoch S. P., Khan A., Inam-ul-Haq, Khan M. A., Mintz E. D. Vibrio cholerae O139 in Karachi, Pakistan. Lancet. 1993 Dec 4;342(8884):1422–1423. doi: 10.1016/0140-6736(93)92780-w. [DOI] [PubMed] [Google Scholar]
  6. Franceschi G., Perrone E., Alpegiani M., Bedeschi A., Battistini C., Zarini F., Della Bruna C. Synthesis and antimicrobial spectrum of FCE 22101 and its orally available ester FCE 22891. J Antimicrob Chemother. 1989 Mar;23 (Suppl 100):1–6. doi: 10.1093/jac/23.suppl_c.1. [DOI] [PubMed] [Google Scholar]
  7. Francis T. I., Lewis E. A., Oyediran A. B., Okubadejo O. A., Montefiore D., Onyewotu I. I., Mohammed I., Ayoola E. A., Vincent R. Effect of chemotherapy on the duration of diarrhoea, and on vibrio excretion by cholera patients. J Trop Med Hyg. 1971 Aug;74(8):172–176. [PubMed] [Google Scholar]
  8. Hall R. H., Khambaty F. M., Kothary M., Keasler S. P. Non-O1 Vibrio cholerae. Lancet. 1993 Aug 14;342(8868):430–430. doi: 10.1016/0140-6736(93)92839-l. [DOI] [PubMed] [Google Scholar]
  9. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother. 1993 Jun;31 (Suppl E):111–117. doi: 10.1093/jac/31.suppl_e.111. [DOI] [PubMed] [Google Scholar]
  10. Inoue E., Mitsuhashi S. In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic. Antimicrob Agents Chemother. 1994 Sep;38(9):1974–1979. doi: 10.1128/aac.38.9.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ishiguro M., Iwata H., Nakatsuka T., Tanaka R., Maeda Y., Nishihara T., Noguchi T., Nishino T. Studies on penem antibiotics. I. Synthesis and in vitro activity of novel 2-chiral substituted penems. J Antibiot (Tokyo) 1988 Nov;41(11):1685–1693. doi: 10.7164/antibiotics.41.1685. [DOI] [PubMed] [Google Scholar]
  12. Kado C. I., Liu S. T. Rapid procedure for detection and isolation of large and small plasmids. J Bacteriol. 1981 Mar;145(3):1365–1373. doi: 10.1128/jb.145.3.1365-1373.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kurazono T., Yamada F., Yamaguchi M., Ohzeki Y., Okuyama Y., Itoh K., Shimada T. [The first report of traveler's diarrhea associated with a newly described toxigenic Vibrio cholerae O139 strain in Japan]. Kansenshogaku Zasshi. 1994 Jan;68(1):8–12. doi: 10.11150/kansenshogakuzasshi1970.68.8. [DOI] [PubMed] [Google Scholar]
  14. LENNOX E. S. Transduction of linked genetic characters of the host by bacteriophage P1. Virology. 1955 Jul;1(2):190–206. doi: 10.1016/0042-6822(55)90016-7. [DOI] [PubMed] [Google Scholar]
  15. Nishino T., Maeda Y., Ohtsu E., Koizuka S., Nishihara T., Adachi H., Okamoto K., Ishiguro M. Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem. J Antibiot (Tokyo) 1989 Jun;42(6):977–988. doi: 10.7164/antibiotics.42.977. [DOI] [PubMed] [Google Scholar]
  16. Pierce N. F., Banwell J. G., Mitra R. C., Caranasos G. J., Keimowitz R. I., Thomas J., Mondal A. Controlled comparison of tetracycline and furazolidone in cholera. Br Med J. 1968 Aug 3;3(5613):277–280. doi: 10.1136/bmj.3.5613.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ramamurthy T., Garg S., Sharma R., Bhattacharya S. K., Nair G. B., Shimada T., Takeda T., Karasawa T., Kurazano H., Pal A. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet. 1993 Mar 13;341(8846):703–704. doi: 10.1016/0140-6736(93)90480-5. [DOI] [PubMed] [Google Scholar]
  18. Retsema J., Girard A., Schelkly W., Manousos M., Anderson M., Bright G., Borovoy R., Brennan L., Mason R. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 1987 Dec;31(12):1939–1947. doi: 10.1128/aac.31.12.1939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sato K., Hoshino K., Tanaka M., Hayakawa I., Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother. 1992 Jul;36(7):1491–1498. doi: 10.1128/aac.36.7.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Washington J. A., 2nd, Wilson W. R. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2). Mayo Clin Proc. 1985 Apr;60(4):271–278. doi: 10.1016/s0025-6196(12)60322-x. [DOI] [PubMed] [Google Scholar]
  21. Womble D. D., Rownd R. H. Genetic and physical map of plasmid NR1: comparison with other IncFII antibiotic resistance plasmids. Microbiol Rev. 1988 Dec;52(4):433–451. doi: 10.1128/mr.52.4.433-451.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Yamamoto T., Koyama Y., Matsumoto M., Sonoda E., Nakayama S., Uchimura M., Paveenkittiporn W., Tamura K., Yokota T., Echeverria P. Localized, aggregative, and diffuse adherence to HeLa cells, plastic, and human small intestines by Escherichia coli isolated from patients with diarrhea. J Infect Dis. 1992 Dec;166(6):1295–1310. doi: 10.1093/infdis/166.6.1295. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES